Jose Dominguez

Dr. Jose Dominguez


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2010 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MSMartina Sester
Martina Sester
Giovanni SotgiuGiovanni Sotgiu
Giovanni Sotgiu
CLChristoph Lange
Christoph Lange
CGC. Giehl
C. Giehl
EGEnrico Girardi
Enrico Girardi
DMD. Manissero
D. Manissero
Interferon-γ release assays (IGRAs) are now established for the immunodiagnosis of latent infection withMycobacterium tuberculosisin many countries. However, the role of IGRAs for the diagnosis of active tuberculosis (TB) remains unclear.Following preferred reporting items for systematic reviews and meta-analyses (PRISMA) and quality assessment of diagnostic accuracy studies (QUADAS) guidelines, we searched PubMed, EMBASE and Cochrane databases to identify studies published in January 2001–November 2009 that evaluated the evidence of using QuantiFERON-TB® Gold in-tube (QFT-G-IT) and T-SPOT.TB®directly on blood or extrasanguinous specimens for the diagnosis of active TB.The literature search yielded 844 studies and 27 met the inclusion criteria. In blood and extrasanguinous fluids, the pooled sensitivity for the diagnosis of active TB was 80% (95% CI 75–84%) and 48% (95% CI 39–58%) for QFT-G-IT, and 81% (95% CI 78–84%) and 88% (confirmed and unconfirmed cases) (95% CI 82–92%) for T-SPOT.TB®, respectively. In blood and extrasanguinous fluids, the pooled specificity was 79% (95% CI 75–82%) and 82% (95% CI 70–91%) for QFT-G-IT, and 59% (95% CI 56–62%) and 82% (95% CI 78–86%) for T-SPOT.TB®, respectively.Although the diagnostic sensitivities of both IGRAs were higher than that of tuberculin skin tests, it was still not high enough to use as a rule out test for TB. Positive evidence for the use of IGRAs in compartments other than blood will require more independent and carefully designed prospective studies.

1 November 2014 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MSMartina Sester
Martina Sester
FLFrank Van Leth
Frank Van Leth
JBJudith Bruchfeld
Judith Bruchfeld
DBDragos Bumbacea
Dragos Bumbacea
DCDaniela M Cirillo
Daniela M Cirillo
TBTbnet
Tbnet
Rationale: In the absence of active tuberculosis, a positive tuberculin skin test (TST) or interferon-γ release assay (IGRA) result defines latent infection with Mycobacterium tuberculosis, although test results may vary depending on immunodeficiency. Objectives: This study compared the performance of TST and IGRAs in five different groups of immunocompromised patients, and evaluated their ability to identify those at risk for development of tuberculosis. Methods: Immunocompromised patients with HIV infection, chronic renal failure, rheumatoid arthritis, solid-organ or stem-cell transplantation, and healthy control subjects were evaluated head-to-head by the TST, QuantiFERON-TB-Gold in-tube test (ELISA), and T-SPOT.TB test (enzyme-linked immunospot) at 17 centers in 11 European countries. Development of tuberculosis was assessed during follow-up. Measurements and Main Results: Frequencies of positive test results varied from 8.7 to 15.9% in HIV infection (n = 768), 25.3 to 30.6% in chronic renal failure (n = 270), 25.0% to 37.2% in rheumatoid arthritis (n = 199), 9.0 to 20.0% in solid-organ transplant recipients (n = 197), 0% to 5.8% in stem-cell transplant recipients (n = 103), and 11.2 to 15.2% in immunocompetent control subjects (n = 211). Eleven patients (10 with HIV infection and one solid-organ transplant recipient) developed tuberculosis during a median follow-up of 1.8 (interquartile range, 0.2–3.0) years. Six of the 11 patients had a negative or indeterminate test result in all three tests at the time of screening. Tuberculosis incidence was generally low, but higher in HIV-infected individuals with a positive TST (3.25 cases per 100 person-years) than with a positive ELISA (1.31 cases per 100 person-years) or enzyme-linked immunospot result (1.78 cases per 100 person-years). No cases of tuberculosis occurred in patients who received preventive chemotherapy. Conclusions: Among immunocompromised patients evaluated in this study, progression toward tuberculosis was highest in HIV-infected individuals and was poorly predicted by TST or IGRAs. Clinical trial registered with www.clinicaltrials.gov (NCT 00707317).

1 January 2001 in Chest
Verified
Journal Article
Closed access
PDF file
JDJose Dominguez
Jose Dominguez
NGNúria Galí
Núria Galí
SBSilvia Blanco
Silvia Blanco
PPPablo Pedroso
Pablo Pedroso
CPCristina Prat
Cristina Prat
VAVicente Ausina
Vicente Ausina

1 May 1998 in Chest
Verified
Journal Article
Closed access
PDF file
NSNieves Sopena
Nieves Sopena
MSMiquel Sabrià-Leal
Miquel Sabrià-Leal
MPMaría Lluisa Pedro-Botet
María Lluisa Pedro-Botet
EPEduardo Padilla
Eduardo Padilla
JDJose Dominguez
Jose Dominguez
PTPere Tudela
Pere Tudela

1 January 2016 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
JDJose Dominguez
Jose Dominguez
EBE C Boettger
E C Boettger
DCD Cirillo
D Cirillo
FCF Cobelens
F Cobelens
KEK D Eisenach
K D Eisenach
RNResist-Tb Networks
Resist-Tb Networks
The emergence of drug-resistant strains of Mycobacterium tuberculosis is a challenge to global tuberculosis (TB) control. Although culture-based methods have been regarded as the gold standard for drug susceptibility testing (DST), molecular methods provide rapid information on mutations in the M. tuberculosis genome associated with resistance to anti-tuberculosis drugs. We ascertained consensus on the use of the results of molecular DST for clinical treatment decisions in TB patients. This document has been developed by TBNET and RESIST-TB groups to reach a consensus about reporting standards in the clinical use of molecular DST results. Review of the available literature and the search for evidence included hand-searching journals and searching electronic databases. The panel identified single nucleotide mutations in genomic regions of M. tuberculosis coding for katG, inhA, rpoB, embB, rrs, rpsL and gyrA that are likely related to drug resistance in vivo. Identification of any of these mutations in clinical isolates of M. tuberculosis has implications for the management of TB patients, pending the results of in vitro DST. However, false-positive and false-negative results in detecting resistance-associated mutations in drugs for which there is poor or unproven correlation between phenotypic and clinical drug resistance complicate the interpretation. Reports of molecular DST results should therefore include specific information on the mutations identified and provide guidance for clinicians on interpretation and on the choice of the appropriate initial drug regimen.

2 December 1999 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
NSN Sopena
N Sopena
MSM Sabrià
M Sabrià
MPM L Pedro-Botet
M L Pedro-Botet
JMJ M Manterola
J M Manterola
LML Matas
L Matas
MFM Foz
M Foz